A Novel Exosomal Inflammatory Pathway

一种新的外泌体炎症途径

基本信息

  • 批准号:
    10541127
  • 负责人:
  • 金额:
    $ 87.76万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2017
  • 资助国家:
    美国
  • 起止时间:
    2017-01-18 至 2023-03-31
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY This Program has defined what some have called a paradigm shifting pathway of neutrophilic inflammation which, unlike the “classic” mode associated with IL-8, can become self-propagating in chronic inflammatory diseases such as COPD. Specifically, IL-8 initiates neutrophil (PMN) influx, the PMNs in turn release matrix metalloproteases (MMPs) and prolyl endopeptidase (PE) which degrade collagen and generate the PMN-specific matrikine, proline-glycine-proline (PGP). In more common acute inflammatory circumstances, the PGP pathway is terminated by the aminopeptidase activity of leukotriene A4 hydrolase (LTA4H) which destroys PGP. Cigarette smoking (CS) can chemically modify and inactivate LTA4H’s aminopeptidase but not hydrolase activity as well as acetylate PGP rendering it immune to LTA4H. This drives persistently elevated PGP levels and chronic neutrophilic inflammation in COPD. In the Program’s journey to understand the PGP system, we have identified a novel potential prognostic biomarker for COPD, CF, and ARDS, linked matrix degradation to vascular leak, and discovered an anti-inflammatory role for a pro-inflammatory enzyme, LTA4H. PGP has also recently been shown to link extracellular matrix degradation to: acute lung injury, inflammatory bowel disease, ischemic brain stroke, and modulation of acute pulmonary infection. Consequently, the discovery of the PGP system has particular significance as a fundamental mediator of pathophysiology in a number of disorders and organs. One enigmatic aspect of our studies has been an inability to generate PGP in vitro with collagen and the appropriate proteases in solution. The thesis of this R35 application is that this enigma is due to the requirement that PGP generating enzymes, such as PE, be exosome associated. This idea is supported by many observations, most notably, that airway exosomes from COPD patients, but not controls, are PMN-derived and cause a COPD-like phenotype when transferred to mice. Collectively, the findings led to our hypothesis that proteolytic exosomes constitute a new aspect of the inflammatory process and may participate in chronic inflammatory disorders such as COPD via the PGP pathway. If successful, the results of this project will define a novel entity, i.e. proteolytic exosome, which drives neutrophilic inflammation via PGP generation which is regulated by LTA4H and can cause a COPD-like disease in mice. In human studies, we will phenotype proteolytic exosomes and delineate whether they are biomarkers of COPD that correlate with disease parameters and can transfer pathology from humans to mice. In a smoking mouse model of COPD we will characterize the evolution of such exosomes and whether they can transfer disease from smoked to naïve animals. Although, the definition of a new pathogenic entity is daunting, the track record of this Program and the expertise of the PI and team suggest a successful endeavor. If so, a complete understanding of the proteolytic exosome may lead to new diagnostics and therapeutics for chronic inflammatory diseases such as COPD.
项目摘要 该计划定义了一些人所谓的嗜中性炎症的范式转移途径 与IL-8相关的“经典”模式不同,其在慢性炎症中可以自我繁殖。 疾病如COPD。具体地,IL-8启动中性粒细胞(PMN)内流,PMN反过来释放基质 金属蛋白酶(MMPs)和脯氨酰内肽酶(PE),其降解胶原并产生PMN特异性的 matrikine,脯氨酸-甘氨酸-脯氨酸(PGP)。在更常见的急性炎症情况下, 被破坏PGP的白三烯A4水解酶(LTA 4 H)的氨肽酶活性终止。香烟 吸烟(CS)可以化学修饰和抑制LTA 4 H的氨肽酶活性,但不能改变水解酶活性 乙酰化PGP使其对LTA 4 H免疫。这导致PGP水平持续升高, COPD中的嗜酸性炎症。在本计划了解PGP系统的过程中, COPD、CF和ARDS的一种新的潜在预后生物标志物,将基质降解与血管渗漏联系起来, 并发现了一种促炎酶LTA 4 H的抗炎作用。PGP最近也被 显示细胞外基质降解与急性肺损伤、炎症性肠病、缺血性脑损伤 中风和急性肺部感染的调节。因此,PGP系统的发现 特别重要的是作为一个基本的调解人的病理生理学在一些疾病和器官。一 我们的研究的一个神秘的方面是无法在体外用胶原蛋白和适当的药物产生PGP。 蛋白酶溶液这个R35应用程序的论点是,这个谜是由于PGP的要求, 产生酶,如PE,是外泌体相关的。这一观点得到了许多观察的支持,大多数 值得注意的是,来自COPD患者而非对照的气道外泌体是PMN衍生的,并引起COPD样的 当转移到小鼠时的表型。总的来说,这些发现导致我们的假设, 构成炎症过程的一个新方面,并可能参与慢性炎症性疾病, 通过PGP途径治疗COPD。如果成功,该项目的结果将定义一个新的实体,即蛋白水解酶。 外泌体,其通过PGP生成驱动嗜酸性炎症,PGP生成受LTA 4 H调节, 导致小鼠患上类似COPD的疾病。在人类研究中,我们将对蛋白水解外泌体进行表型分析, 它们是否是COPD的生物标志物,与疾病参数相关,并且可以将病理学从 人类到老鼠在COPD的吸烟小鼠模型中,我们将表征这种外泌体的进化, 它们是否能将疾病从烟熏动物身上传染给未感染的动物。虽然,新致病性的定义 实体是令人生畏的,该计划的跟踪记录和PI和团队的专业知识表明, 奋进。如果是这样的话,对蛋白水解外泌体的完全理解可能会导致新的诊断方法, 用于慢性炎性疾病如COPD的治疗剂。

项目成果

期刊论文数量(9)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Benzyloxycarbonyl-proline-prolinal (ZPP): Dual complementary roles for neutrophil inhibition.
苄氧羰基-脯氨酸-脯氨酸 (ZPP):中性粒细胞抑制的双重互补作用。
  • DOI:
    10.1016/j.bbrc.2019.07.111
  • 发表时间:
    2019
  • 期刊:
  • 影响因子:
    3.1
  • 作者:
    Russell,DW;Hardison,M;Genschmer,KR;Szul,T;Bratcher,PE;AbdulRoda,M;Xu,X;Viera,L;Blalock,JE;Gaggar,A;Noerager,BD
  • 通讯作者:
    Noerager,BD
Therapeutic effect of two strategies directed at disruption of pathogenic neutrophil extracellular vesicles in a murine emphysema model.
两种针对小鼠肺气肿模型中致病性中性粒细胞胞外囊泡破坏策略的治疗效果。
The Matrikine Acetylated Proline-Glycine-Proline Couples Vascular Inflammation and Acute Cardiac Rejection.
Matrikine 乙酰化脯氨酸-甘氨酸-脯氨酸与血管炎症和急性心脏排斥反应相关。
  • DOI:
    10.1038/s41598-017-07610-0
  • 发表时间:
    2017
  • 期刊:
  • 影响因子:
    4.6
  • 作者:
    Payne,GregoryA;Li,Jindong;Xu,Xin;Jackson,Patricia;Qin,Hongwei;Pollock,DavidM;Wells,JMichael;Oparil,Suzanne;Leesar,Massoud;Patel,RakeshP;Blalock,JEdwin;Gaggar,Amit
  • 通讯作者:
    Gaggar,Amit
A mechanism for matrikine regulation in acute inflammatory lung injury.
急性炎症性肺损伤中苦参碱调节的机制。
  • DOI:
    10.1172/jci.insight.140750
  • 发表时间:
    2021
  • 期刊:
  • 影响因子:
    8
  • 作者:
    Robison,SarahW;Li,JinDong;Viera,Liliana;Blackburn,JonathanP;Patel,RakeshP;Blalock,JEdwin;Gaggar,Amit;Xu,Xin
  • 通讯作者:
    Xu,Xin
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

J Edwin Blalock其他文献

J Edwin Blalock的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('J Edwin Blalock', 18)}}的其他基金

Pathogenic Exosomes in COPD
COPD 中的致病性外泌体
  • 批准号:
    10571796
  • 财政年份:
    2023
  • 资助金额:
    $ 87.76万
  • 项目类别:
A Novel Exosomal Inflammatory Pathway
一种新的外泌体炎症途径
  • 批准号:
    10540601
  • 财政年份:
    2017
  • 资助金额:
    $ 87.76万
  • 项目类别:
A Novel Exosomal Inflammatory Pathway
一种新的外泌体炎症途径
  • 批准号:
    10320741
  • 财政年份:
    2017
  • 资助金额:
    $ 87.76万
  • 项目类别:
Genetics of Smoke-Altered LTA4H in COPD
COPD 中烟雾改变的 LTA4H 的遗传学
  • 批准号:
    9502350
  • 财政年份:
    2015
  • 资助金额:
    $ 87.76万
  • 项目类别:
Genetics of Smoke-Altered LTA4H in COPD
COPD 中烟雾改变的 LTA4H 的遗传学
  • 批准号:
    9281903
  • 财政年份:
    2015
  • 资助金额:
    $ 87.76万
  • 项目类别:
Acquired LTA4H Dysfunction in COPD
COPD 患者获得性 LTA4H 功能障碍
  • 批准号:
    8366816
  • 财政年份:
    2012
  • 资助金额:
    $ 87.76万
  • 项目类别:
Acquired LTA4H Dysfunction in COPD
COPD 患者获得性 LTA4H 功能障碍
  • 批准号:
    8857226
  • 财政年份:
    2012
  • 资助金额:
    $ 87.76万
  • 项目类别:
PGP, A Possible Biomarker for COPD Exacerbations and or Progression
PGP,COPD 恶化和/或进展的可能生物标志物
  • 批准号:
    8881993
  • 财政年份:
    2012
  • 资助金额:
    $ 87.76万
  • 项目类别:
Acquired LTA4H Dysfunction in COPD
COPD 患者获得性 LTA4H 功能障碍
  • 批准号:
    8515516
  • 财政年份:
    2012
  • 资助金额:
    $ 87.76万
  • 项目类别:
PGP, A Possible Biomarker for COPD Exacerbations and or Progression
PGP,COPD 恶化和/或进展的可能生物标志物
  • 批准号:
    8334299
  • 财政年份:
    2012
  • 资助金额:
    $ 87.76万
  • 项目类别:

相似海外基金

Combinatorial cytokine-coated macrophages for targeted immunomodulation in acute lung injury
组合细胞因子包被的巨噬细胞用于急性肺损伤的靶向免疫调节
  • 批准号:
    10648387
  • 财政年份:
    2023
  • 资助金额:
    $ 87.76万
  • 项目类别:
Inducible HMGB1 antagonist for viral-induced acute lung injury.
诱导型 HMGB1 拮抗剂,用于治疗病毒引起的急性肺损伤。
  • 批准号:
    10591804
  • 财政年份:
    2023
  • 资助金额:
    $ 87.76万
  • 项目类别:
MAP2K1 AND MAP2K2 IN ACUTE LUNG INJURY AND RESOLUTION
MAP2K1 和 MAP2K2 在急性肺损伤中的作用及缓解
  • 批准号:
    10741574
  • 财政年份:
    2023
  • 资助金额:
    $ 87.76万
  • 项目类别:
Lung epithelial cell-derived C3 in acute lung injury
肺上皮细胞衍生的 C3 在急性肺损伤中的作用
  • 批准号:
    10720687
  • 财政年份:
    2023
  • 资助金额:
    $ 87.76万
  • 项目类别:
Examining the role of TRMT1 and tRNA methylation in acute lung injury and ARDS
检查 TRMT1 和 tRNA 甲基化在急性肺损伤和 ARDS 中的作用
  • 批准号:
    10719249
  • 财政年份:
    2023
  • 资助金额:
    $ 87.76万
  • 项目类别:
Development of a new treatment for COVID-19-related acute lung injury targeting the microbiota-derived peptide corisin
针对微生物群衍生肽 corisin 开发治疗 COVID-19 相关急性肺损伤的新疗法
  • 批准号:
    23K07651
  • 财政年份:
    2023
  • 资助金额:
    $ 87.76万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Probing immunovascular mechanobiology in pneumonia-associated acute lung injury at the single capillary level
在单毛细血管水平探讨肺炎相关急性肺损伤的免疫血管力学生物学
  • 批准号:
    10679944
  • 财政年份:
    2023
  • 资助金额:
    $ 87.76万
  • 项目类别:
The amyloid precursor protein protects against acute lung injury
淀粉样前体蛋白可预防急性肺损伤
  • 批准号:
    10575258
  • 财政年份:
    2023
  • 资助金额:
    $ 87.76万
  • 项目类别:
Role of macrophages and miRNA in regulating lung macrophage polarization and lung pathogenesis during respiratory virus-induced acute lung injury in normal and diabetic Syrian hamsters.
正常和糖尿病叙利亚仓鼠呼吸道病毒引起的急性肺损伤期间巨噬细胞和 miRNA 在调节肺巨噬细胞极化和肺部发病机制中的作用。
  • 批准号:
    10701207
  • 财政年份:
    2023
  • 资助金额:
    $ 87.76万
  • 项目类别:
Roles of N-glycans on neutrophil beta2 integrins in progression of acute lung injury
N-聚糖对中性粒细胞β2整合素在急性肺损伤进展中的作用
  • 批准号:
    10837431
  • 财政年份:
    2023
  • 资助金额:
    $ 87.76万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了